Key Points
- Amy Horton, Artivion's CAO, sold 4,572 shares on Dec. 8 at an average price of $44.42 for $203,088 and now holds 130,058 shares, a 3.4% reduction; she also sold 6,000 (Nov. 17), 3,482 (Nov. 13) and 1,789 (Nov. 10) shares in recent weeks.
- Artivion reported an earnings beat for the quarter (EPS $0.16 vs. $0.14) with revenue up 18.9% year‑over‑year, and its shares trade in the mid‑$40s (50‑day SMA $44.10, 1‑year high $48.04).
- Wall Street sentiment is broadly positive—several firms raised targets (Needham to $58) and the stock has an average target of $49.11 with a consensus rating of "Moderate Buy" (7 buys, 1 hold, 1 sell).
Artivion, Inc. (NYSE:AORT - Get Free Report) CAO Amy Horton sold 4,572 shares of Artivion stock in a transaction on Monday, December 8th. The shares were sold at an average price of $44.42, for a total value of $203,088.24. Following the completion of the sale, the chief accounting officer owned 130,058 shares in the company, valued at $5,777,176.36. This represents a 3.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Amy Horton also recently made the following trade(s):
- On Monday, November 17th, Amy Horton sold 6,000 shares of Artivion stock. The stock was sold at an average price of $45.73, for a total value of $274,380.00.
- On Thursday, November 13th, Amy Horton sold 3,482 shares of Artivion stock. The shares were sold at an average price of $45.86, for a total transaction of $159,684.52.
- On Monday, November 10th, Amy Horton sold 1,789 shares of Artivion stock. The shares were sold at an average price of $44.62, for a total transaction of $79,825.18.
Artivion Price Performance
Shares of AORT opened at $43.32 on Wednesday. The firm has a 50-day simple moving average of $44.10 and a two-hundred day simple moving average of $38.45. The stock has a market cap of $2.05 billion, a PE ratio of -180.50 and a beta of 1.60. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $48.04. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.93 and a quick ratio of 2.88.
Artivion (NYSE:AORT - Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.02. Artivion had a negative net margin of 2.16% and a positive return on equity of 5.98%. The firm had revenue of $113.39 million during the quarter, compared to the consensus estimate of $110.71 million. The company's revenue for the quarter was up 18.9% compared to the same quarter last year. As a group, analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.
Wall Street Analysts Forecast Growth
Several research firms recently issued reports on AORT. Needham & Company LLC boosted their price objective on Artivion from $50.00 to $58.00 and gave the company a "buy" rating in a report on Friday, November 7th. Canaccord Genuity Group raised their target price on Artivion from $50.00 to $51.00 and gave the company a "buy" rating in a report on Friday, November 7th. LADENBURG THALM/SH SH downgraded Artivion from a "buy" rating to a "neutral" rating and lifted their target price for the company from $32.00 to $38.80 in a research report on Wednesday, August 13th. Wall Street Zen raised shares of Artivion from a "buy" rating to a "strong-buy" rating in a research report on Saturday, November 15th. Finally, Citizens Jmp raised their price objective on shares of Artivion from $47.00 to $53.00 and gave the company a "market outperform" rating in a research note on Friday, November 7th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $49.11.
Read Our Latest Stock Analysis on Artivion
Institutional Trading of Artivion
Several hedge funds have recently added to or reduced their stakes in the company. Verition Fund Management LLC grew its holdings in Artivion by 1.6% during the 3rd quarter. Verition Fund Management LLC now owns 16,912 shares of the company's stock worth $716,000 after acquiring an additional 274 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in shares of Artivion by 1.8% in the 3rd quarter. State of Alaska Department of Revenue now owns 23,294 shares of the company's stock valued at $985,000 after purchasing an additional 414 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Artivion by 6.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company's stock worth $349,000 after purchasing an additional 477 shares during the last quarter. Van ECK Associates Corp lifted its position in shares of Artivion by 19.0% during the 3rd quarter. Van ECK Associates Corp now owns 3,176 shares of the company's stock worth $134,000 after purchasing an additional 506 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund grew its stake in shares of Artivion by 5.8% during the third quarter. Oregon Public Employees Retirement Fund now owns 9,329 shares of the company's stock worth $395,000 after purchasing an additional 510 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company's stock.
About Artivion
(
Get Free Report)
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
